Literature DB >> 9383689

Long-term treatment of indomethacin reduces vertebral bone mass and strength in ovariectomized rats.

H Saino1, T Matsuyama, J Takada, T Kaku, S Ishii.   

Abstract

We investigated the effect of the long-term treatment of indomethacin, on lumbar spinal bone mineral density (LSBMD), cancellous bone mass, structure, and strength of vertebral body in old ovariectomized (OVX) rats. Ten-month-old female Wistar rats were divided into five groups: the sham operated + vehicle (sham + VEH) group, the OVX + vehicle (OVX + VEH) group, the OVX + indomethacin (IN) 1.5 mg/kg/week (OVX + IN1.5) group, the OVX + IN 6.0 mg/kg/week (OVX + IN6.0) group, and the OVX + IN 15.0 mg/kg/week (OVX + IN15.0) group. IN or vehicle were given by subcutaneous injection (s.c.) three times per week. The treatments were started at 1 week after operation and continued for 24 weeks. LSBMD (L2-L5) was measured at 0, 12, and 24 weeks after the beginning of treatment. At the end of the experimental period, the animals were sacrificed, and bone histomorphometrical and biomechanical analysis of lumbar vertebral body were done. LSBMD, trabecular bone volume (BV/TV), and trabecular thickness (Tb.Th) decreased significantly in a dose-related manner with IN. In the OVX + IN15.0 group, LSBMD decreased by 12.7%, BV/TV decreased by 65.5%, and Tb.Th decreased by 32.8%, compared with the OVX + VEH group. In addition, the maximum stress in a compressive mechanical test of L4 vertebral body in OVX groups was also decreased in a dose-related manner with IN, and this value in the OVX + IN15.0 group was 31.3% lower than in the OVX + VEH group. We conclude that long-term treatment with IN accentuated the OVX-related decrease in trabecular bone mass and the compressive strength of lumbar vertebrae.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9383689     DOI: 10.1359/jbmr.1997.12.11.1844

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  6 in total

1.  Anabolic effects of a G protein-coupled receptor kinase inhibitor expressed in osteoblasts.

Authors:  Robert F Spurney; Patrick J Flannery; Sanford C Garner; Krairerk Athirakul; Shiguang Liu; Farshid Guilak; L Darryl Quarles
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

2.  The relation between osteoporosis and vitamin D levels and disease activity in ankylosing spondylitis.

Authors:  Bedriye Mermerci Başkan; Yasemin Pekin Doğan; Filiz Sivas; Hatice Bodur; Kürşat Ozoran
Journal:  Rheumatol Int       Date:  2009-08-14       Impact factor: 2.631

Review 3.  Skeletal sequelae of cancer and cancer treatment.

Authors:  Charles J Stava; Camilo Jimenez; Mimi I Hu; Rena Vassilopoulou-Sellin
Journal:  J Cancer Surviv       Date:  2009-05-02       Impact factor: 4.442

4.  Timing of ibuprofen use and bone mineral density adaptations to exercise training.

Authors:  Wendy M Kohrt; Daniel W Barry; Rachael E Van Pelt; Catherine M Jankowski; Pamela Wolfe; Robert S Schwartz
Journal:  J Bone Miner Res       Date:  2010-06       Impact factor: 6.741

Review 5.  Cyclooxygenase-2 inhibitors: promise or peril?

Authors:  Laurel J Mengle-Gaw; Benjamin D Schwartz
Journal:  Mediators Inflamm       Date:  2002-10       Impact factor: 4.711

6.  Perioperative alendronate, risedronate, calcitonin and indomethacin treatment alters femoral stem fixation and periprosthetic bone mineral density in ovariectomized rats.

Authors:  Deniz Cankaya; Yalcin Tabak; Akif Muhtar Ozturk; Muhammed Cuneyd Gunay
Journal:  J Orthop Sci       Date:  2015-03-26       Impact factor: 1.601

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.